Loading

Financial Press Releases

About Avicanna

Strategically positioned to be a front runner in the;
• Development
• Manufacturing and;
• Commercialization of plant-derived cannabinoid-based products

Dec. 8, 2020

Avicanna Announces Closing of Public Offering of Units

TORONTO, ON, Dec. 8, 2020 /CNW/ – Avicanna Inc. (“Avicanna”, or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce the closing of its previously announced marketed public offering of 5,966,900 units (the “Units”) of the Company at a price of $0.85 per Unit, for gross proceeds of $5,071,865 (the “Offering”). Each Unit is comprised of one common share of the Company …

Nov. 12, 2020

Avicanna Announces Overnight Marketed Public Offering of Units

TORONTO, Nov. 12, 2020 /CNW/ – Avicanna Inc. (“Avicanna“, or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that it has filed and has been receipted for a preliminary short form prospectus with the securities commissions in Alberta, British Columbia, Manitoba, Ontario and Saskatchewan (the …

Nov. 12, 2020

Avicanna Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces results for the third quarter ended September 30, 2020 Aras Azadian, Chief Executive …

Aug. 18, 2020

Avicanna Closes Non-Brokered Private Placement Raising $2.7 Million

Avicanna Inc. is pleased to announce that it has closed a non-brokered private placement (the “Offering“). Under the Offering, the Company has issued an aggregate of 1,952,410 units (the “Units“) at a price of CAD$1.40 per Unit for aggregate gross proceeds of approximately CAD$2.7 million. Under the Offering, the Company has issued an aggregate of 1,952,410 …

Avicanna Reports Second Quarter 2020 Financial Results and Provides Corporate Update – Aug 17, 2020
Avicanna Reports First Quarter 2020 Financial Results and Provides Corporate Update – May 25, 2020
Avicanna Closes Non-Brokered Private – Placement with Group of Strategic Investors and Announces Warrant Re-Pricing – April 21, 2020
Avicanna Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update – April 15, 2020
Avicanna Closes First Tranche of Private Placement – January 24, 2020
Avicanna Reports Third Quarter 2019 Financial Results – Nov. 14, 2019
Avicanna Completes its First Exportation of Cannabinoids from Colombia to Canada for Scientific Purposes – Aug 23, 2019
Avicanna Reports Second Quarter 2019 Financial Results – Aug 14, 2019
Avicanna Commences Trading on the TSX Under the Symbol “AVCN” – July 18, 2019
Avicanna Announces TSX Listing Date – July 16, 2019
Avicanna Announces Receipt for Final Prospectus and Conditional Approval for Listing on the TSX – July 10, 2019
Avicanna Closes Oversubscribed $22.1 Million Special Warrant Offering – April 18, 2019
Avicanna Announces Filing of Preliminary Prospectus – January 21, 2019
Avicanna Inc. Acquires 60% Stake in Colombian Medical Marijuana Firm Santa Marta Golden Hemp – August 16, 2018
Avicanna Completes 2nd Equity Financing & Welcomes New Strategic Shareholder – January 29, 2018
Avicanna Closes its First Equity Financing and Announces its Residency at Johnson & Johnson Innovation, JLABS @ Toronto – May 26, 2017

avica_white

480 University Ave, Suite 1502
Toronto, ON M5G 1V2
Canada

Want to stay up to date? Subscribe to receive email updates.

           
© 2017-2019 Avicanna Inc. All Rights Reserved.
Subscribe
SUBSCRIBE NOW

Sign up and join our Newsletter  

Stay updated with all latest
updates and news.
close-link